Image Source: UnsplashAn IntroductionThis article highlights the 10 clinical-stage AI-powered (designated with *) and psychedelic compound-based (designated with **) small cap ($400M to $2.0B) drug discovery companies in the munKNEE Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week, in descending order, and MTD and their areas of focus, along with their latest news, analyses and commentary where available.
- focuses on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine. Go here for much more extensive information on DMT.
- Latest news, commentary and/or analysis:
- Recent Price Trend in GH Research is Your Friend, Here’s Why
- develops antibody therapeutics and then outsources their initial findings to their partners for further drug discovery.
- Latest news, commentary and/or analysis:
- AbCellera Reports Q1 2024 Business Results
- specializes in developing an artificial intelligence-driven allosteric drug-discovery platform intended to detect and characterize interactions that occur on a protein of interest and combines computational methods with experimental approaches across the fields of structural biology, biophysics, and chemistry. Its initial focus on precision oncology and genetic diseases.
- Latest news, commentary and/or analysis:
- Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
- focuses on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
- Latest news, commentary and/or analysis:
- MindMed Reports 1stQ 2024 Financial Results
- has one of the world’s most extensive biological and chemical datasets and has several compounds in phase 1 and 2 studies, including a small molecule therapeutic for cavernous cerebral malformation and another for neurofibromatosis type 2.
- Latest news, commentary and/or analysis:
- Here is What to Know Beyond Why Recursion Pharmaceuticals is a Trending Stock
- specializes in offering solutions for both small molecule discovery and biologics discovery focusing on structure prediction and protein engineering, including antibody modeling.
- Latest news, commentary and/or analysis:
- Schrödinger Reports First Quarter 2024 Financial Results
- focuses on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Latest news, commentary and/or analysis:
- These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring
- focuses on the use of ketamine, DMT and ibogaine. Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
- Latest news, commentary and/or analysis:
- atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
- focuses on antibody design, creating new from scratch antibodies (“de novo antibodies”), and testing them in laboratories in a 6-week process.
- Latest news, commentary and/or analysis:
- Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
- reported the first AI-designed drug candidate to enter clinical trials and is collaborating with Bristol-Myers Squibb on a handful of drug candidates and has partnered with Sanofi, GSK and PathAI on drug discovery projects.
- Latest news, commentary and/or analysis:
- Analysts Are Upgrading Exscientia After Its Latest Results
- Analysts Are Upgrading Exscientia After Its Latest Results
SummaryOn average, the above 10 stocks were DOWN 1.1% last week and are now DOWN 0.6% MTD and DOWN 11.7% YTD.More By This Author:AI Category Returns Were A Mixed Bag This Week
Update: Ai Pin Widely Panned; Humane Announces It’s For Sale
These AI Stocks Have Momentum Up And Down
